SCHEMBL5356331

SCHEMBL5356331

Nc1nc2ccccc2c2c1ncn2CCCCSc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 11/20 0.57
LMNA P02545 1/20 0.57
POLB P06746 1/20 0.57
HRH2 P25021 1/20 0.57
ADRA1D P25100 1/20 0.57
HTR2A P28223 1/20 0.57
ADORA2A P29274 1/20 0.57
ADRA1A P35348 1/20 0.57
NUDT1 P36639 1/20 0.57
HTR2B P41595 1/20 0.57
PDE4D Q08499 1/20 0.57
KCNH2 Q12809 1/20 0.57
CYP1A2 P05177 2/20 0.54
CYP2D6 P10635 2/20 0.54
CYP2C9 P11712 2/20 0.54
CYP2C19 P33261 2/20 0.54
CYP3A4 P08684 1/20 0.45
MAPT P10636 1/20 0.45
TLR8 Q9NR97 6/20 0.40
MAPK13 O15264 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5360305 0.92 TLR7 (0.60) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL5369858 0.87 TLR7 (0.61) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL5355612 0.84 TLR7 (0.63) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL3821194 0.84 TLR7 (0.63) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL6106909 0.83 TLR7 (0.59) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL3868909 0.83 TLR7 (0.62) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL1335078 0.83 TLR7 (0.62) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL8136496 0.83 TLR7 (0.62) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL22803635 0.83 TLR7 (0.65) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL8136290 0.83 TLR7 (0.62) TLR7LMNAPOLBHRH2ADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1541572-A1 Thioether substituted imidazoquinolines 3M Innovative Properties Company (US) 2005-06-15 EP claimed
EP-1341791-B1 THIOETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2005-05-25 EP claimed
US-20040102471-A1 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-05-27 US claimed
US-20040097736-A1 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-05-20 US claimed
US-6664264-B2 Thioether substituted imidazoquinoline or tetrahydroimdazoquinoline compounds induce the biosynthesis of cytokines such as interferon and useful for treating viral disease in an animal 3M INNOVATIVE PROPERTIES COMPANY 2003-12-16 US claimed
US-20030100764-A1 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2003-05-29 US claimed
US-20020173655-A1 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2002-11-21 US claimed
US-7288550-B2 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-10-30 US disclosed
US-7288550-B2 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-10-30 US disclosed
US-7288550-B2 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-10-30 US disclosed
US-7276515-B2 Thioether substituted imidazoquinolines COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-10-02 US disclosed
US-7276515-B2 Thioether substituted imidazoquinolines COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-10-02 US disclosed
US-7276515-B2 Thioether substituted imidazoquinolines COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-10-02 US disclosed
US-6667312-B2 Useful as immune response modifiers 3M INNOVATIVE PROPERTIES COMPANY 2003-12-23 US disclosed
US-6664264-B2 Thioether substituted imidazoquinoline or tetrahydroimdazoquinoline compounds induce the biosynthesis of cytokines such as interferon and useful for treating viral disease in an animal 3M INNOVATIVE PROPERTIES COMPANY 2003-12-16 US disclosed
EP-1341791-A2 THIOETHER SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2003-09-10 EP disclosed
WO-2003050121-A1 THIOETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-06-19 WO disclosed
US-20030100764-A1 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2003-05-29 US disclosed
US-20020173655-A1 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2002-11-21 US disclosed
WO-2002046192-A2 THIOETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097736-A1 Thioether substituted imidazoquinolines IFNG, IRF3, IL2 TLR7 30/4885LMNA 4785/4885POLB 3882/4885
US-20020173655-A1 Thioether substituted imidazoquinolines IFNG, IRF3, IL2 TLR7 30/4885LMNA 4785/4885POLB 3882/4885
US-20040102471-A1 Thioether substituted imidazoquinolines IFNG, IRF3, IL2 TLR7 30/4885LMNA 4785/4885POLB 3882/4885
US-20030100764-A1 Thioether substituted imidazoquinolines IFNG, IRF3, IL2 TLR7 30/4885LMNA 4785/4885POLB 3882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.